A UConn researcher explores whether the benefits of approving a drug before it’s clear that it works outweighs the potential costs.

Boston Biz Journal https://www.bizjournals.com/boston/news/2021/06/10/the-fda-s-big-gamble-on-the-new-alzheimer-s-drug.html?ana=RSS&s=article_search